Accession Therapeutics Limited
PrivateLast Round
Grant
Mar 24, 2026
Est. Valuation
$100.93M
Total Funding Raised
$44.23M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Accession Therapeutics Limited operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Grant round in March 2026.
Accession Therapeutics Limited is a biopharmaceutical company developing a novel class of tumour-targeted immunotherapies through its proprietary TROCEPT platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accession Therapeutics Limited Comparables
Compare Accession Therapeutics Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| KaliVir Immunotherapeutics | 87% | |
| TILT Biotherapeutics | 87% | |
| Theolytics | 86% |
For institutional investors. Book with your work email.
Accession Therapeutics Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 24, 2026 | ||||
| VC Round | Mar 18, 2026 | ||||
| VC Round | Dec 4, 2025 | ||||
| VC Round | Apr 25, 2024 | ||||
| Series A | Nov 21, 2022 | ||||
Seed | Sep 20, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Accession Therapeutics Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Birk Venture | Seed, Series A |
| Cancer Research UK | Series A |
| iGlobe Partners | VC Round, Series A |
| Primavera Venture Partners | Seed, VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 67% MoM.
- Mar 24, 2026
Received $9M in grant funding from the European Commission.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 19, 2026
On Oct 19th '26, Accession Therapeutics Limited appoints Pierre d'Epenoux as a Non-Executive Director to its Board in the United Kingdom.
- hiresOct 19, 2026
Accession Therapeutics Limited appoints Martin Nicklasson as Non-Executive Chairman in United Kingdom on Oct 19th '26, replacing Nick Cross, who remains a Board Director.
For institutional investors. Book with your work email.
Accession Therapeutics Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Accession Therapeutics Limited's valuation, stock price, and market status.
Is Accession Therapeutics Limited a public or private company?
Accession Therapeutics Limited is a private company.
What is the current stock price of Accession Therapeutics Limited?
Accession Therapeutics Limited is a private company, so its shares have no public market price. Caplight tracks Accession Therapeutics Limited's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Accession Therapeutics Limited worth (valuation)?
Accession Therapeutics Limited's valuation is estimated at $100.9M based on funding round data.
Can I buy Accession Therapeutics Limited stock?
Accession Therapeutics Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Accession Therapeutics Limited's last funding round?
Accession Therapeutics Limited's most recent funding round was Grant on March 24, 2026.
Who are the main investors in Accession Therapeutics Limited?
Key investors in Accession Therapeutics Limited include iGlobe Partners, Primavera Venture Partners.
Will Accession Therapeutics Limited IPO soon?
No public IPO plans have been announced for Accession Therapeutics Limited.
How can I track Accession Therapeutics Limited secondary market activity?
Caplight tracks bids, offers, and trades in Accession Therapeutics Limited's shares on secondary markets.